https://ir.scorpiusbiologics.com/ https://ir.scorpiusbiologics.com/news-events/press-releases https://ir.scorpiusbiologics.com/news-events/ir-calendar https://ir.scorpiusbiologics.com/news-events/presentations https://ir.scorpiusbiologics.com/news-events/email-alerts https://ir.scorpiusbiologics.com/company-information https://ir.scorpiusbiologics.com/company-information/contacts https://ir.scorpiusbiologics.com/financial-information/financial-results https://ir.scorpiusbiologics.com/financial-information/income-statement https://ir.scorpiusbiologics.com/financial-information/balance-sheet https://ir.scorpiusbiologics.com/financial-information/cash-flow https://ir.scorpiusbiologics.com/stock-data/quote-chart https://ir.scorpiusbiologics.com/stock-data/historical-data https://ir.scorpiusbiologics.com/stock-data/analyst-coverage https://ir.scorpiusbiologics.com/sec-filings/all-sec-filings https://ir.scorpiusbiologics.com/sec-filings/annual-reports https://ir.scorpiusbiologics.com/sec-filings/quarterly-reports https://ir.scorpiusbiologics.com/sec-filings/section-16-filings https://ir.scorpiusbiologics.com/corporate-governance https://ir.scorpiusbiologics.com/corporate-governance/board-committees https://ir.scorpiusbiologics.com/corporate-governance/governance-documents https://ir.scorpiusbiologics.com/news-events/press-releases/detail/781/scorpius-holdings-announces-corporate-update-including-cost-optimization-initiatives-strategic-corporate-developments-and-potential-opportunities-for-expansion-into-southeast-asia https://ir.scorpiusbiologics.com/news-events/press-releases/detail/780/scorpius-holdings-provides-2024-year-end-business-update-implements-strategic-cost-reductions-and-operational-streamlining https://ir.scorpiusbiologics.com/news-events/press-releases/detail/779/scorpius-holdings-receives-nyse-american-notice-of-delisting-and-reports-plans-to-appeal https://ir.scorpiusbiologics.com/news-events/press-releases/detail/778/scorpius-holdings-engages-alliance-global-partners-to-explore-strategic-alternatives https://ir.scorpiusbiologics.com/news-events/press-releases/detail/777/scorpius-holdings-announces-collaboration-with-kalocyte-to-advance-manufacturing-for-erythromer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/776/scorpius-holdings-cancels-planned-reverse-stock-split https://ir.scorpiusbiologics.com/news-events/press-releases/detail/775/scorpius-holdings-announces-reverse-stock-split https://ir.scorpiusbiologics.com/news-events/press-releases/detail/774/scorpius-holdings-launches-scorpius-ventures-to-support-u-s-biotech-innovation-through-flexible-equity-based-onshoring-model https://ir.scorpiusbiologics.com/news-events/press-releases/detail/773/scorpius-holdings-reports-third-quarter-2024-results-highlighting-strategic-partnerships-cost-savings-and-progress-toward-profitability https://ir.scorpiusbiologics.com/news-events/press-releases/detail/772/scorpius-holdings-announces-collaboration-with-celltheon-corporation-a-u-s--based-cell-line-development-company-first-client-signed-under-new-partnership-agreement https://ir.scorpiusbiologics.com/news-events/press-releases/detail/771/scorpius-holdings-announces-implementation-of-new-cost-savings-measures-expected-to-save-over-2-million-annually https://ir.scorpiusbiologics.com/news-events/press-releases/detail/770/scorpius-holdings-announces-partnership-with-u-s-biotech-company https://ir.scorpiusbiologics.com/news-events/press-releases/detail/769/scorpius-holdings-selected-to-join-medical-cbrn-defense-consortium-to-advance-medical-countermeasures-against-chemical-biological-radiological-and-nuclear-threats https://ir.scorpiusbiologics.com/news-events/press-releases/detail/768/scorpius-holdings-announces-contract-with-premier-clinical-stage-biotech-company-opens-door-to-future-gmp-manufacturing-opportunities https://ir.scorpiusbiologics.com/news-events/press-releases/detail/767/scorpius-holdings-commends-the-u-s-house-of-representatives-passage-of-the-biosecure-act https://ir.scorpiusbiologics.com/news-events/press-releases/detail/766/scorpius-selected-for-rapid-response-partnership-vehicle-rrpv-to-accelerate-medical-countermeasure-development-in-support-of-barda https://ir.scorpiusbiologics.com/news-events/press-releases/detail/765/scorpius-holdings-ceo-provides-corporate-update-highlights-expanding-sales-pipeline-enhanced-manufacturing-capabilities-and-path-toward-positive-cash-flow https://ir.scorpiusbiologics.com/news-events/press-releases/detail/764/scorpius-holdings-achieves-16-year-over-year-increase-in-revenue-for-the-second-quarter-of-2024 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/763/scorpius-holdings-inc-announces-closing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/762/scorpius-holdings-inc-announces-pricing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/761/scorpius-holdings-inc-provides-update-on-itspreviously-announced-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/760/scorpius-holdings-weighted-average-pipeline-surpasses-100-million-in-business-develop-opportunities-across-both-manufacturing-client-and-government-sectors https://ir.scorpiusbiologics.com/news-events/press-releases/detail/759/scorpius-holdings-announces-removal-of-nyse-american-trading-suspension-expected-to-resume-normal-trading-on-august-2-2024 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/758/scorpius-holdings-set-to-launch-first-mammalian-cgmp-campaign-at-san-antonio-facility-in-the-2024-3rd-quarter https://ir.scorpiusbiologics.com/news-events/press-releases/detail/757/scorpius-holdings-receives-nyse-american-notice-of-delisting-and-reports-plans-to-appeal https://ir.scorpiusbiologics.com/news-events/press-releases/detail/756/scorpius-holdings-and-beyond-imagination-announce-trailblazing-partnership-to-utilize-autonomous-ai-powered-humanoid-robots-for-american-biomanufacturing https://ir.scorpiusbiologics.com/news-events/press-releases/detail/755/scorpius-holdings-achieves-359-year-over-year-increase-in-revenue-for-the-first-quarter-of-2024 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/754/scorpius-holdings-announces-major-expansion-in-san-antonio-with-new-state-of-the-art-storage-and-testing-facility https://ir.scorpiusbiologics.com/news-events/press-releases/detail/753/scorpius-holdings-inc-announces-closing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/752/scorpius-holdings-commends-congress-on-bipartisan-legislative-action-aimed-at-bolstering-u-s-biomanufacturing https://ir.scorpiusbiologics.com/news-events/press-releases/detail/751/scorpius-holdings-achieves-major-milestone-with-cgmp-facility-validation-for-microbial-manufacturing https://ir.scorpiusbiologics.com/news-events/press-releases/detail/750/scorpius-holdings-inc-announces-pricing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/749/scorpius-holdings-appoints-new-vp-of-business-development-shari-udoff-mcdonald https://ir.scorpiusbiologics.com/news-events/press-releases/detail/748/scorpius-holdings-provides-2023-year-end-business-update-reports-570-sequential-increase-in-revenue-for-the-fourth-quarter-of-2023 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/747/scorpius-holdings-announces-receipt-of-filing-delinquency-notification https://ir.scorpiusbiologics.com/news-events/press-releases/detail/746/scorpius-holdings-awarded-contract-in-excess-of-1-million-with-nih-fundedresearcher-at-a-major-university https://ir.scorpiusbiologics.com/news-events/press-releases/detail/745/scorpius-holdings-accepted-as-a-member-of-the-us-governments-biomap-consortium https://ir.scorpiusbiologics.com/news-events/press-releases/detail/744/scorpius-holdings-inc-announces-closing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/743/scorpius-holdings-inc-announces-pricing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/742/scorpius-holdings-inc-announces-proposed-public-offering-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/741/scorpius-holdings-estimates-greater-than-375-sequential-increase-in-revenue-for-the-fourth-quarter-of-2023-compared-to-the-third-quarter-of-2023 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/740/nighthawk-biosciences-completes-name-change-to-scorpius-holdings-trading-to-commence-under-scpx-effective-at-the-market-open-today https://ir.scorpiusbiologics.com/news-events/press-releases/detail/739/nighthawks-scorpius-biomanufacturing-subsidiary-announces-the-promotion-of-joe-payne-to-president-and-chief-operating-officer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/738/nighthawk-receives-proceeds-of-3-25-million-in-connection-with-sale-of-non-core-intellectual-property-and-issuance-of-a-low-interest-bearing-note https://ir.scorpiusbiologics.com/news-events/press-releases/detail/737/nighthawks-scorpius-biomanufacturing-subsidiary-awarded-multimillion--dollar-contract-with-a-publicly-traded-biotech-company-to-support-its-phase-2-clinical-program https://ir.scorpiusbiologics.com/news-events/press-releases/detail/736/nighthawks-scorpius-biomanufacturing-subsidiary-commences-work-on-preclinical-program-for-new-client https://ir.scorpiusbiologics.com/news-events/press-releases/detail/735/nighthawk-biosciences-announces-planned-name-change-to-scorpius-holdings-reflecting-successful-transition-to-a-large-molecule-biomanufacturing-cdmo https://ir.scorpiusbiologics.com/news-events/press-releases/detail/734/nighthawk-biosciences-commences-work-on-multi-million-dollar-development-and-manufacturing-agreement-for-a-leading-national-university https://ir.scorpiusbiologics.com/news-events/press-releases/detail/733/nighthawk-biosciences-announces-completion-of-demonstration-run-for-a-top-tier-nih-and-dtra-funded-research-university https://ir.scorpiusbiologics.com/news-events/press-releases/detail/732/nighthawk-biosciences-announces-major-milestone-with-completion-of-manufacturing-run-for-a-premier-u-s--based-biopharmaceutical-company https://ir.scorpiusbiologics.com/news-events/press-releases/detail/731/nighthawk-biosciences-announces-strategic-shift-into-a-pure-play-large-molecule-biomanufacturing-cdmo-to-capitalize-on-rapid-growth-in-sales-pipeline-along-with-divestiture-of-non-core-assets https://ir.scorpiusbiologics.com/news-events/press-releases/detail/730/nighthawk-biosciences-provides-q3-2023-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/729/nighthawk-biosciences-provides-q2-2023-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/728/nighthawk-biosciences-provides-q1-2023-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/727/nighthawk-biosciences-provides-2022-year-end-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/726/nighthawk-biosciences-provides-third-quarter-2022-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/725/nighthawk-biosciences-scorpion-subsidiary-announces-grand-opening-of-its-san-antonio-facility https://ir.scorpiusbiologics.com/news-events/press-releases/detail/724/nighthawk-biosciences-announces-buildout-of-advancedbiosafety-level-2-bsl-2-laboratory https://ir.scorpiusbiologics.com/news-events/press-releases/detail/723/nighthawk-biosciences-provides-second-quarter-2022-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/722/nighthawk-biosciences-appoints-stephan-kutzer-ph-d-as-interim-chief-executive-officer-of-scorpion-biological-services https://ir.scorpiusbiologics.com/news-events/press-releases/detail/721/nighthawk-biosciences-provides-first-quarter-2022-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/720/nighthawk-biosciences-to-present-at-the-4th-annual-treg-directed-therapies-summit-on-ptx-35 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/719/heat-biologics-completes-name-change-to-nighthawk-biosciences-trading-to-commence-under-nhwk-effective-at-the-market-open-today https://ir.scorpiusbiologics.com/news-events/press-releases/detail/718/heat-biologics-nighthawk-biosciences-announces-that-its-elusys-therapeutics-subsidiary-has-executed-a-contract-to-deliver-anthim-to-the-canadian-government https://ir.scorpiusbiologics.com/news-events/press-releases/detail/717/heat-biologics-nighthawk-biosciences-completes-acquisition-of-elusys-therapeutics https://ir.scorpiusbiologics.com/news-events/press-releases/detail/716/heat-biologics-announces-planned-name-change-to-nighthawk-biosciences-reflecting-companys-evolution-therapeutic-pipeline-expansion-vertical-integration-and-new-biodefense-capabilities https://ir.scorpiusbiologics.com/news-events/press-releases/detail/715/reminder-heat-biologics-to-host-planned-investor-and-media-livestream-event-on-tuesday-april-19th-at-10-30-am-et-to-discuss-latest-developments https://ir.scorpiusbiologics.com/news-events/press-releases/detail/714/heat-biologics-scorpion-subsidiary-announces-planned-development-of-new-kansas-commercialbiodefense-biomanufacturing-facility https://ir.scorpiusbiologics.com/news-events/press-releases/detail/713/heat-biologics-announces-planned-investor-and-media-livestream-eventto-discuss-latest-developments https://ir.scorpiusbiologics.com/news-events/press-releases/detail/712/heat-biologics-unveils-enhanced-allogeneic-cell-manufacturing-process https://ir.scorpiusbiologics.com/news-events/press-releases/detail/711/heat-biologics-announces-appointment-of-greg-burel-former-director-of-the-strategic-national-stockpile-to-its-biothreat-advisory-board-and-as-senior-advisor-to-the-company https://ir.scorpiusbiologics.com/news-events/press-releases/detail/710/heat-biologics-provides-year-end-2021-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/709/heat-biologics-announces-planned-transfer-to-the-nyse-american https://ir.scorpiusbiologics.com/news-events/press-releases/detail/708/elusys-therapeutics-finalizes-hhs-contract-to-deliver-anthim-its-treatment-for-inhalation-anthrax-to-the-u-s-department-of-health-and-human-services https://ir.scorpiusbiologics.com/news-events/press-releases/detail/707/heat-biologics-announces-new-ptx-35-preclinical-data-in-organ-transplantation-and-provides-update-on-hs-110 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/706/heat-biologics-announces-planned-acquisition-of-elusys-therapeutics https://ir.scorpiusbiologics.com/news-events/press-releases/detail/705/heat-biologics-unveils-rapidvax-a-novel-cellular-vaccine-platform-targeting-known-and-unknown-emerging-biological-threats https://ir.scorpiusbiologics.com/news-events/press-releases/detail/704/heat-biologics-provides-third-quarter-2021-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/703/heat-biologics-appoints-paul-tebbey-as-senior-vice-president-of-product-development-and-portfolio-strategy https://ir.scorpiusbiologics.com/news-events/press-releases/detail/702/heat-biologics-ceo-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-on-september-29th https://ir.scorpiusbiologics.com/news-events/press-releases/detail/701/heat-biologics-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/700/heat-biologics-to-provide-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/699/heat-biologics-unveils-skunkworx-bio-new-drug-discovery-subsidiary https://ir.scorpiusbiologics.com/news-events/press-releases/detail/698/heat-biologics-announces-addition-of-former-us-senatormark-pryor-to-biothreat-advisory-board https://ir.scorpiusbiologics.com/news-events/press-releases/detail/697/heat-biologics-announces-new-additions-to-biothreat-advisory-board https://ir.scorpiusbiologics.com/news-events/press-releases/detail/696/heat-biologics-announces-formation-of-biothreat-advisory-board https://ir.scorpiusbiologics.com/news-events/press-releases/detail/695/heat-biologics-provides-second-quarter-2021-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/694/heat-biologics-announces-groundbreaking-for-new-san-antonio-facility https://ir.scorpiusbiologics.com/news-events/press-releases/detail/693/heat-biologics-joins-russell-microcap-index https://ir.scorpiusbiologics.com/news-events/press-releases/detail/692/heat-biologics-announces-significant-expansion-of-rd-and-pre-clinical-capabilities-at-corporate-headquarters https://ir.scorpiusbiologics.com/news-events/press-releases/detail/691/heat-biologics-to-showcase-favorable-survival-data-of-hs-110-in-previously-treated-non-small-cell-lung-cancer-patients-at-2021-american-society-of-clinical-oncology-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/690/heat-biologics-announces-promising-survival-data-of-hs-110-in-two-treatment-settings-of-lung-cancer-selected-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/689/heat-biologics-announces-multiple-presentations-on-ptx-35-at-theupcoming-3rd-annual-treg-directed-therapies-summit https://ir.scorpiusbiologics.com/news-events/press-releases/detail/688/heat-biologics-appoints-anthony-manning-ph-d-as-chief-scientific-advisor https://ir.scorpiusbiologics.com/news-events/press-releases/detail/687/heat-biologics-provides-first-quarter-2021-business-update-reports-continued-progress-on-oncology-and-covid-19-vaccine-programs https://ir.scorpiusbiologics.com/news-events/press-releases/detail/686/heat-biologics-announces-new-preclinical-data-on-ptx-35-demonstrating-decreased-regulatory-t-cell-treg-activity-and-delayed-tumor-progression-at-american-association-for-cancer-research-aacr-annual-meeting-2021 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/685/heat-biologics-provides-year-end-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/684/heat-biologics-to-participate-at-m-vest-llc-and-maxim-group-llc-inaugural-emerging-growth-virtual-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/683/heat-biologics-to-present-at-2021-bio-ceo-investor-digital-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/682/heat-biologics-announces-positive-interim-survival-data-from-ongoing-hs-110-phase-2-non-small-cell-lung-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/681/heat-biologics-announces-publication-of-additional-preclinical-covid-19-vaccine-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/680/heat-biologics-ceo-to-participate-in-a-fireside-chat-at-the-b-riley-securities-oncology-investor-conference-on-jan-21-2021 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/679/heat-biologics-commences-manufacturing-process-for-zvx-60 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/678/heat-biologics-promotes-william-l-ostrander-to-chief-financial-officer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/677/heat-biologics-to-present-at-the-h-c-wainwright-virtual-bioconnect-2021-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/676/heat-biologics-announces-completion-of-zvx-60-vaccine-cell-line-for-covid-19 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/675/heat-biologics-provides-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/674/heat-biologics-provides-third-quarter-2020-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/673/heat-biologics-issued-additional-patent-on-gp96-combination-platform-therapy-with-t-cell-co-stimulator https://ir.scorpiusbiologics.com/news-events/press-releases/detail/672/heat-biologics-ceo-to-participate-in-virtual-panel-new-approaches-to-covid-19-hidden-breakthroughs-on-thursday-september-10th https://ir.scorpiusbiologics.com/news-events/press-releases/detail/671/heat-biologics-issued-key-patent-on-combination-platform-therapy https://ir.scorpiusbiologics.com/news-events/press-releases/detail/670/heat-biologics-announces-publication-of-preclinical-covid-19-vaccine-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/669/heat-biologics-covid-19-vaccine-demonstrates-robust-t-cell-driven-immune-response-to-sars-cov-2-in-preclinical-studies https://ir.scorpiusbiologics.com/news-events/press-releases/detail/668/heat-biologics-provides-second-quarter-2020-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/667/heat-biologics-highlights-importance-of-t-cell-immunity-to-prevent-covid-19 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/666/heat-biologics-covid-19-vaccine-demonstrates-immunogenicity-proof-of-concept-in-pre-clinical-studies https://ir.scorpiusbiologics.com/news-events/press-releases/detail/665/heat-biologics-regains-compliance-with-nasdaq-minimum-bid-price-rule https://ir.scorpiusbiologics.com/news-events/press-releases/detail/664/heat-biologics-announces-first-patient-treated-in-first-in-human-clinical-trial-of-ptx-35 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/663/heat-biologics-announces-initiation-of-the-lead-clinical-trial-site-for-ptx-35 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/662/heat-biologics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-ptx-35 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/661/heat-biologics-provides-update-on-covid-19-vaccine-efforts https://ir.scorpiusbiologics.com/news-events/press-releases/detail/660/heat-biologics-presents-positive-survival-benefit-for-hs-110-in-combination-with-nivolumab-in-phase-2-lung-cancer-trial-at-2020-american-society-of-clinical-oncology-asco-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/659/heat-biologics-announces-collaboration-with-waisman-biomanufacturing-to-manufacture-covid-19-vaccine https://ir.scorpiusbiologics.com/news-events/press-releases/detail/658/heat-biologics-provides-first-quarter-2020-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/657/positive-survival-data-from-phase-2-lung-cancer-trial-accepted-for-presentation-at-2020-american-society-of-clinical-oncology-asco-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/656/heat-biologics-provides-clinical-update-reports-continued-progress-advancing-hs-110 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/655/heat-biologics-reports-progress-on-covid-19-efforts-and-timeline-of-anticipated-q2-2020-milestones https://ir.scorpiusbiologics.com/news-events/press-releases/detail/654/heat-biologics-announces-formation-of-covid-19-advisory-board https://ir.scorpiusbiologics.com/news-events/press-releases/detail/653/heat-biologics-provides-year-end-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/652/heat-biologics-and-university-of-miami-developing-proprietary-covid-19-diagnostic-test-under-collaborative-research-agreement https://ir.scorpiusbiologics.com/news-events/press-releases/detail/651/heat-biologics-invited-to-join-the-alliance-for-biosecurity https://ir.scorpiusbiologics.com/news-events/press-releases/detail/650/heat-biologics-inc-to-present-at-the-spring-investor-summit-on-march-25th-26th-in-new-york-city https://ir.scorpiusbiologics.com/news-events/press-releases/detail/649/heat-biologics-announces-research-collaboration-with-university-of-miami-to-develop-vaccine-designed-to-protect-against-covid-19-coronavirus https://ir.scorpiusbiologics.com/news-events/press-releases/detail/648/heat-biologics-ceo-to-appear-today-on-abc11-wtvd-to-discuss-the-companys-newly-launched-program-to-develop-a-vaccine-to-protect-against-sars-cov-2-coronavirus-that-causes-covid-19 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/647/heat-biologics-launches-program-to-develop-vaccine-designed-to-protect-against-covid-19-coronavirus https://ir.scorpiusbiologics.com/news-events/press-releases/detail/646/heat-biologics-inc-announces-closing-of-7000000-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/645/heat-biologics-inc-prices-7000000-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/644/heat-biologics-announces-first-patient-dosed-in-the-first-phase-1-trial-of-hs-130 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/643/heat-biologics-announces-additional-positive-top-line-phase-2-data-of-hs-110-plus-nivolumab-in-advanced-nsclc-patients https://ir.scorpiusbiologics.com/news-events/press-releases/detail/642/heat-biologics-announces-additional-top-line-phase-2-data-of-hs-110-plus-nivolumab-in-advanced-nsclc-patients-at-aacr-tumor-immunology-and-immunotherapy-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/641/heat-biologics-reports-third-quarter-2019-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/640/heat-biologics-presents-additional-phase-2-interim-data-in-advanced-nsclc-patients-at-the-sitc-34th-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/639/heat-biologics-reports-positive-phase-2-interim-data-in-nsclc-patients-who-previously-failed-checkpoint-inhibitor-treatment https://ir.scorpiusbiologics.com/news-events/press-releases/detail/638/heat-biologics-announces-a-poster-presentation-of-updated-top-line-phase-2-data-of-hs-110-plus-nivolumab-after-checkpoint-inhibitor-treatment-failure-in-nsclc-patients-at-the-sitc-34th-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/637/heat-biologics-reports-second-quarter-2019-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/636/heat-biologics-announces-fda-clearance-of-ind-application-to-begin-phase-1-trial-of-hs-130-in-combination-with-heats-hs-110 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/635/heat-biologics-ceo-and-lead-director-to-participate-in-german-investor-forums https://ir.scorpiusbiologics.com/news-events/press-releases/detail/634/heat-biologics-completes-enrollment-in-phase-2-non-small-cell-lung-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/633/heat-biologics-announces-promising-interim-phase-2-lung-cancer-data-suggesting-that-hs-110-plus-nivolumab-may-restore-clinical-benefit-after-checkpoint-inhibitor-treatment-failure https://ir.scorpiusbiologics.com/news-events/press-releases/detail/632/heat-biologics-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/631/heat-biologics-reports-first-quarter-2019-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/630/heat-biologics-lead-director-to-present-at-the-chinabio-2019-conference-in-shanghai https://ir.scorpiusbiologics.com/news-events/press-releases/detail/629/heat-biologics-ceo-to-present-at-the-thinkequity-conference-in-new-york-city https://ir.scorpiusbiologics.com/news-events/press-releases/detail/628/heat-biologics-delivers-poster-presentation-at-the-aacr-annual-meeting-2019 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/627/heat-biologics-reports-2018-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/626/heat-biologics-to-present-at-the-chinese-society-for-clinical-oncology-conference-on-immunotherapy https://ir.scorpiusbiologics.com/news-events/press-releases/detail/625/heat-biologics-lead-director-to-chair-oncology-roundtable-discussion-at-wuxi-healthcare-forum-in-shanghai https://ir.scorpiusbiologics.com/news-events/press-releases/detail/624/heat-biologics-presents-interim-phase-2-lung-cancer-data-on-hs-110-nivolumab-at-asco-sitc-clinical-immuno-oncology-symposium https://ir.scorpiusbiologics.com/news-events/press-releases/detail/623/update-heat-biologics-doses-first-patient-in-new-cohort-of-its-expanded-phase-2-trial-of-hs-110-in-combination-with-mercks-keytrudar-in-non-small-cell-lung-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/622/heat-biologics-doses-first-patient-in-new-cohort-of-its-expanded-phase-2-trial-of-hs-110-in-combination-with-mercks-keytrudar-in-non-small-cell-lung-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/621/heat-biologics-provides-clinical-and-business-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/620/heat-biologics-principal-investigator-selected-to-deliver-oral-presentation-of-new-hs-110-interim-phase-2-data-at-the-2019-asco-sitc-clinical-immuno-oncology-symposium https://ir.scorpiusbiologics.com/news-events/press-releases/detail/619/heat-biologics-to-present-at-biotech-showcase-2019-in-california https://ir.scorpiusbiologics.com/news-events/press-releases/detail/618/heat-biologics-inc-announces-closing-of-13800000-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/617/heat-biologics-to-participate-in-panel-presentation-at-the-goldman-sachs-asia-pacific-healthcare-forum https://ir.scorpiusbiologics.com/news-events/press-releases/detail/616/heat-biologics-inc-prices-12000000-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/615/heat-biologics-inc-announces-proposed-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/614/heat-biologics-reports-third-quarter-2018-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/613/heat-biologics-to-present-at-precision-lung-cancer-world-rd-summit https://ir.scorpiusbiologics.com/news-events/press-releases/detail/612/heat-biologics-ceo-to-participate-in-panel-presentation-at-the-cellular-living-drug-revolution-summit-in-new-york-city https://ir.scorpiusbiologics.com/news-events/press-releases/detail/611/heat-biologics-to-present-at-the-2018-bio-investor-forum https://ir.scorpiusbiologics.com/news-events/press-releases/detail/608/heat-biologics-pelican-subsidiary-provides-update-on-its-novel-ptx-35-t-cell-costimulator https://ir.scorpiusbiologics.com/news-events/press-releases/detail/607/heat-biologics-to-present-at-the-20th-annual-rodman-renshaw-global-investment-conference-in-new-york-city https://ir.scorpiusbiologics.com/news-events/press-releases/detail/606/heat-biologics-reports-second-quarter-2018-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/605/heat-biologics-to-present-at-the-2018-bio-international-convention https://ir.scorpiusbiologics.com/news-events/press-releases/detail/604/heat-biologics-reports-first-quarter-2018-results-and-provides-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/603/heat-biologics-inc-announces-closing-of-20-7-million-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/602/heat-biologics-inc-prices-18000000-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/601/heat-biologics-announces-upcoming-milestones-following-positive-interim-phase-2-results-for-hs-110 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/600/heat-biologics-reports-positive-data-to-further-support-the-mechanism-of-action-for-its-proprietary-t-cell-activation-platform https://ir.scorpiusbiologics.com/news-events/press-releases/detail/599/heat-biologics-and-its-pelican-therapeutics-subsidiary-appoint-anthony-tolcher-m-d-frcpc-facp-to-their-scientific-advisory-boards https://ir.scorpiusbiologics.com/news-events/press-releases/detail/598/heat-biologics-to-present-at-the-b-riley-fbr-inaugural-china-healthcare-investing-partnering-symposium https://ir.scorpiusbiologics.com/news-events/press-releases/detail/597/heat-biologics-to-present-at-the-bio-europe-spring-conference-march-12-14-2018-in-amsterdam https://ir.scorpiusbiologics.com/news-events/press-releases/detail/596/heat-biologics-adopts-stockholder-rights-plan https://ir.scorpiusbiologics.com/news-events/press-releases/detail/595/heat-biologics-reports-fiscal-year-2017-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/594/heat-biologics-announces-positive-interim-data-from-its-phase-2-clinical-trial-of-hs-110-and-nivolumab-in-non-small-cell-lung-cancer-nsclc https://ir.scorpiusbiologics.com/news-events/press-releases/detail/593/update-heat-biologics-to-host-analyst-and-investor-event-february-28-2018-to-present-results-from-its-phase-2-lung-cancer-study https://ir.scorpiusbiologics.com/news-events/press-releases/detail/592/heat-biologics-receives-recommendation-from-independent-data-monitoring-committee-to-continue-enrollment-of-phase-2-clinical-trial-for-hs-110-and-nivolumab-for-treatment-of-non-small-cell-lung-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/591/heat-biologics-announces-poster-presentation-of-interim-phase-2-lung-cancer-clinical-data-for-hs-110-and-nivolumab-at-the-2018-keystone-symposia-conference-xi-immunological-memory-innate-adaptive-and-beyond https://ir.scorpiusbiologics.com/news-events/press-releases/detail/590/heat-biologics-ceo-jeff-wolf-to-present-at-the-upcoming-bio-ceo-investor-conference-in-new-york https://ir.scorpiusbiologics.com/news-events/press-releases/detail/589/heat-biologics-to-host-analyst-and-investor-event-february-28-2018-to-present-results-from-its-phase-2-lung-cancer-study https://ir.scorpiusbiologics.com/news-events/press-releases/detail/588/heat-biologics-announces-reverse-stock-split https://ir.scorpiusbiologics.com/news-events/press-releases/detail/587/heat-biologics-receives-fda-guidance-at-type-c-meeting-for-hs-110-clinical-trial-in-the-treatment-of-non-small-cell-lung-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/586/heat-biologics-prices-5813950-shares-for-common-stock-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/585/heat-biologics-announces-proposed-public-offering-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/584/heat-biologics-reports-third-quarter-2017-results-and-corporate-update https://ir.scorpiusbiologics.com/news-events/press-releases/detail/583/heat-biologics-presents-follow-up-data-on-its-compact-t-cell-stimulating-platform-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/582/heat-biologics-to-present-data-on-its-compact-technology-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/581/pelican-therapeutics-a-subsidiary-of-heat-biologics-receives-second-tranche-of-its-15-2-million-cprit-grant-award https://ir.scorpiusbiologics.com/news-events/press-releases/detail/580/heat-biologics-rights-offering-materials-available-for-shareholders-of-record https://ir.scorpiusbiologics.com/news-events/press-releases/detail/579/heat-biologics-and-its-pelican-therapeutics-subsidiary-appoint-two-new-members-to-their-scientific-advisory-boards https://ir.scorpiusbiologics.com/news-events/press-releases/detail/578/heat-biologics-announces-pricing-for-rights-offering-to-stockholders-and-participating-warrant-holders https://ir.scorpiusbiologics.com/news-events/press-releases/detail/577/update-heat-biologics-to-present-at-the-upcoming-bio-investor-forum-in-san-francisco https://ir.scorpiusbiologics.com/news-events/press-releases/detail/576/heat-biologics-announces-expected-calendar-for-rights-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/575/pelican-therapeutics-announces-manufacturing-agreement-with-kbi-biopharma-to-advance-cancer-targeting-immunotherapies https://ir.scorpiusbiologics.com/news-events/press-releases/detail/574/heat-biologics-announces-common-stock-rights-offering-in-form-s-1-filing https://ir.scorpiusbiologics.com/news-events/press-releases/detail/573/heat-biologics-granted-type-c-meeting-with-fda-to-discuss-registrational-pathway-for-hs-110-in-combination-with-opdivor-as-a-treatment-for-non-small-cell-lung-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/572/heat-biologics-to-present-at-the-19th-annual-rodman-renshaw-global-investment-conference-in-new-york https://ir.scorpiusbiologics.com/news-events/press-releases/detail/571/heat-biologics-inc-reports-second-quarter-2017-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/570/dr-jeff-hutchins-appointed-chief-operating-officer-for-heat-biologics https://ir.scorpiusbiologics.com/news-events/press-releases/detail/569/heat-biologics-appoints-damien-hallet-as-vice-president-of-cmc-development https://ir.scorpiusbiologics.com/news-events/press-releases/detail/568/pelican-therapeutics-a-subsidiary-of-heat-biologics-receives-first-tranche-of-15-2-million-cprit-grant-award https://ir.scorpiusbiologics.com/news-events/press-releases/detail/567/heat-biologics-to-present-at-the-2017-bio-international-convention https://ir.scorpiusbiologics.com/news-events/press-releases/detail/566/heat-biologics-to-present-at-the-2017-marcum-microcap-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/565/heat-biologics-presents-poster-on-its-phase-2-trial-evaluating-hs-410-at-asco-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/564/heat-biologics-to-present-poster-at-2017-asco-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/563/heat-biologics-provides-business-and-clinical-update-for-the-first-quarter-of-2017 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/562/heat-biologics-announces-completion-of-acquisition-of-pelican-therapeutics https://ir.scorpiusbiologics.com/news-events/press-releases/detail/561/heat-biologics-to-present-at-pioneers-2017-presented-by-joseph-gunnar-co https://ir.scorpiusbiologics.com/news-events/press-releases/detail/560/heat-biologics-presents-new-preclinical-data-from-oncosec-collaboration-at-the-american-association-for-cancer-research-aacr-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/559/heat-biologics-reports-fiscal-year-2016-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/558/heat-biologics-closes-public-offering-of-5000000-shares-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/557/heat-biologics-prices-offering-of-5000000-shares-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/556/heat-biologics-announces-proposed-public-offering-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/555/heat-biologics-reports-positive-interim-phase-2-lung-cancer-results-in-patients-treated-with-hs-110-in-combination-with-a-checkpoint-inhibitor https://ir.scorpiusbiologics.com/news-events/press-releases/detail/554/heat-biologics-inc-to-present-at-the-microcap-conference-on-april-4th-in-new-york-city https://ir.scorpiusbiologics.com/news-events/press-releases/detail/553/florida-department-of-health-awards-three-year-grant-to-develop-gp96-based-zika-vaccine https://ir.scorpiusbiologics.com/news-events/press-releases/detail/552/heat-biologics-meets-efficacy-endpoint-in-its-phase-1b-lung-cancer-trial-to-progress-to-phase-2 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/551/heat-biologics-to-present-at-29th-annual-roth-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/550/heat-biologics-announces-agreement-to-acquire-pelican-therapeutics https://ir.scorpiusbiologics.com/news-events/press-releases/detail/549/heat-biologics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/548/heat-biologics-presents-immune-data-on-its-hs-410-phase-2-bladder-cancer-trial-at-the-genitourinary-cancers-symposium https://ir.scorpiusbiologics.com/news-events/press-releases/detail/547/heat-biologics-to-present-at-the-genitourinary-cancers-symposium https://ir.scorpiusbiologics.com/news-events/press-releases/detail/546/heat-biologics-to-present-at-noblecon13 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/545/heat-biologics-to-present-at-biotech-showcase-2017-conference-in-san-francisco https://ir.scorpiusbiologics.com/news-events/press-releases/detail/544/heat-biologics-appoints-jeff-hutchins-ph-d-as-chief-scientific-officer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/543/heat-biologics-presents-topline-hs-110nivolumab-combination-lung-cancer-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/542/heat-biologics-presents-topline-hs-410-phase-2-bladder-cancer-results-at-the-society-of-urological-oncology-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/541/heat-biologics-to-present-topline-hs-110nivolumab-combination-phase-ib-lung-cancer-results-at-the-international-society-for-the-study-of-lung-cancer-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/540/heat-biologics-to-present-topline-hs-410-phase-ii-bladder-cancer-results-at-the-society-of-urological-oncology-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/539/heat-biologics-presents-compact-preclinical-data-at-the-society-for-immunotherapy-of-cancer-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/538/heat-biologics-provides-corporate-update-and-reports-third-quarter-2016-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/537/heat-biologics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/536/heat-biologics-and-university-of-miami-announce-zika-vaccine-collaboration https://ir.scorpiusbiologics.com/news-events/press-releases/detail/535/heat-biologics-to-present-at-two-upcoming-investor-conferences-and-panel-discussion https://ir.scorpiusbiologics.com/news-events/press-releases/detail/534/heat-biologics-remains-on-track-to-achieve-multiple-topline-data-readouts-this-quarter https://ir.scorpiusbiologics.com/news-events/press-releases/detail/533/heat-biologics-selects-adaptive-biotechnologies-to-discover-potential-clinical-biomarkers-to-advance-novel-immunotherapies https://ir.scorpiusbiologics.com/news-events/press-releases/detail/532/heat-biologics-substantially-reduces-debt-and-reports-proceeds-of-approximately-2-8-million-year-to-date-from-the-exercise-of-warrants https://ir.scorpiusbiologics.com/news-events/press-releases/detail/531/heat-biologics-resumes-enrollment-in-its-non-small-cell-lung-cancer-trial-evaluating-hs-110-in-combination-with-anti-pd-1-checkpoint-inhibitor https://ir.scorpiusbiologics.com/news-events/press-releases/detail/530/heat-biologics-to-present-at-two-upcoming-investor-conferences https://ir.scorpiusbiologics.com/news-events/press-releases/detail/529/heat-biologics-provides-corporate-update-and-reports-second-quarter-2016-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/528/heat-biologics-announces-suspension-of-proposed-public-offering-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/527/heat-biologics-announces-proposed-public-offering-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/526/heat-biologics-announces-cancer-immunology-research-publication-featuring-its-compact-platform-technology https://ir.scorpiusbiologics.com/news-events/press-releases/detail/525/heat-biologics-presents-a-poster-on-its-hs-110nivolumab-combination-phase-1b-non-small-cell-lung-cancer-trial-at-asco-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/524/heat-biologics-reports-first-quarter-2016-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/523/heat-biologics-to-present-at-pioneers-2016-presented-by-joseph-gunnar-co https://ir.scorpiusbiologics.com/news-events/press-releases/detail/522/heat-biologics-appoints-dr-john-prendergast-to-board-of-directors https://ir.scorpiusbiologics.com/news-events/press-releases/detail/521/heat-biologics-and-oncosec-present-data-at-the-american-conference-for-cancer-research-aacr-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/520/heat-biologics-to-present-at-the-american-association-for-cancer-research-aacr-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/519/heat-biologics-announces-cost-saving-measures-and-focused-corporate-strategy-to-achieve-important-clinical-milestones https://ir.scorpiusbiologics.com/news-events/press-releases/detail/518/heat-biologics-to-participate-in-the-6th-annual-cancer-immunotherapy-a-long-awaited-reality-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/517/heat-biologics-announces-closing-of-public-offering https://ir.scorpiusbiologics.com/news-events/press-releases/detail/516/heat-biologics-announces-public-offering-of-common-stock-and-warrants https://ir.scorpiusbiologics.com/news-events/press-releases/detail/515/heat-biologics-cso-to-participate-in-the-27th-annual-cancer-progress-conference-by-defined-health https://ir.scorpiusbiologics.com/news-events/press-releases/detail/514/heat-biologics-presents-positive-compact-preclinical-data-at-the-keystone-symposia https://ir.scorpiusbiologics.com/news-events/press-releases/detail/513/heat-biologics-to-present-at-the-28th-annual-roth-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/512/heat-biologics-provides-update-on-its-hs-410-phase-2-monotherapy-bladder-cancer-trial-arm https://ir.scorpiusbiologics.com/news-events/press-releases/detail/511/heat-biologics-reports-fiscal-year-2015-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/510/fda-lifts-heat-biologics-partial-clinical-hold https://ir.scorpiusbiologics.com/news-events/press-releases/detail/509/heat-biologics-reports-update-on-its-hs-410-phase-2-bladder-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/508/heat-biologics-cso-to-present-interim-results-from-the-monotherapy-arm-in-its-ongoing-hs-410-phase-2-bladder-cancer-trial-at-the-phacilitate-immunotherapy-world-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/507/heat-biologics-to-present-at-biotech-showcase-2016 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/506/heat-biologics-appoints-timothy-creech-as-chief-financial-officer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/505/heat-biologics-selected-as-one-of-informas-2015-top-10-immuno-oncology-companies-to-watch https://ir.scorpiusbiologics.com/news-events/press-releases/detail/504/heat-biologics-reports-hs-410-phase-1-bladder-cancer-trial-results-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/503/results-of-heat-biologics-hs-410-phase-1-safety-trial-in-non-muscle-invasive-bladder-cancer-to-be-presented-at-sitc-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/502/heat-biologics-releases-third-quarter-2015-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/501/heat-biologics-expands-scientific-and-clinical-advisory-board-with-appointments-of-drs-holbrook-kohrt-and-kapil-dhingra https://ir.scorpiusbiologics.com/news-events/press-releases/detail/500/heat-biologics-completes-patient-enrollment-for-randomized-arms-of-its-phase-2-hs-410-bladder-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/499/heat-biologics-to-participate-in-the-annual-prostate-cancer-foundation-scientific-retreat https://ir.scorpiusbiologics.com/news-events/press-releases/detail/498/heat-biologics-to-present-new-data-on-its-compact-platform-at-the-cri-cimt-eati-aacr-inaugural-international-cancer-immunotherapy-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/497/heat-biologics-inc-to-present-at-the-17th-annual-global-investment-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/496/heat-biologics-announces-clinical-trial-combining-hs-110-and-pd-1-checkpoint-inhibitor-in-nsclc https://ir.scorpiusbiologics.com/news-events/press-releases/detail/495/heat-biologics-announces-financial-results-for-the-second-quarter-ended-june-30-2015 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/494/heat-biologics-inc-announces-promotions-of-taylor-schreiber-m-d-ph-d-to-chief-scientific-officer-and-melissa-price-ph-d-to-vice-president-of-product-development https://ir.scorpiusbiologics.com/news-events/press-releases/detail/493/heat-biologics-inc-to-present-at-the-cantor-fitzgerald-healthcare-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/492/heat-biologics-announces-development-of-compact-a-next-generation-combination-immunotherapy-platform https://ir.scorpiusbiologics.com/news-events/press-releases/detail/491/heat-biologics-inc-to-present-interim-immune-response-data-from-ongoing-phase-ii-trial-with-hs-110-in-advanced-nsclc-at-asco https://ir.scorpiusbiologics.com/news-events/press-releases/detail/490/heat-biologics-inc-to-present-at-the-marcum-microcap-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/489/heat-biologics-announces-financial-results-for-the-first-quarter-ended-march-31-2015 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/610/correcting-and-replacing----heat-biologics-announces-initiation-of-phase-1b-trial-of-viagenpumatucel-l-hs-110-in-non-small-cell-lung-cancer-nsclc https://ir.scorpiusbiologics.com/news-events/press-releases/detail/488/heat-biologics-announces-initiation-of-phase-1b-trial-of-viagenpumatucel-l-hs-110-in-non-small-cell-lung-cancer-nsclc https://ir.scorpiusbiologics.com/news-events/press-releases/detail/486/heat-biologics-inc-to-present-at-the-2015-american-association-for-cancer-research-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/485/heat-biologics-inc-to-present-at-the-2015-american-association-for-cancer-research-annual-meeting https://ir.scorpiusbiologics.com/news-events/press-releases/detail/484/heat-biologics-announces-financial-results-for-the-year-ended-december-31-2014 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/474/heat-biologics-inc-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-the-underwriters-over-allotment-option https://ir.scorpiusbiologics.com/news-events/press-releases/detail/464/heat-biologics-inc-announces-pricing-of-public-offering-of-10660000-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/454/heat-biologics-inc-announces-proposed-public-offering-of-common-stock https://ir.scorpiusbiologics.com/news-events/press-releases/detail/444/heat-biologics-inc-receives-us-fda-fast-track-designation-for-hs-410-vesigenurtacel-l-in-combination-with-bcg-for-the-treatment-of-non-muscle-invasive-bladder-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/434/heat-biologics-provides-update-at-key-opinion-leader-event https://ir.scorpiusbiologics.com/news-events/press-releases/detail/424/heat-biologics-inc-to-host-key-opinion-leader-meeting-on-february-26-in-new-york-city https://ir.scorpiusbiologics.com/news-events/press-releases/detail/414/heat-biologics-inc-and-oncosec-medical-inc-announce-collaboration-to-evaluate-combination-of-immunotherapy-platforms https://ir.scorpiusbiologics.com/news-events/press-releases/detail/404/heat-biologics-presents-positive-preclinical-data-on-a-novel-approach-to-combination-immunotherapy-at-the-keystone-symposia-on-tumor-immunology https://ir.scorpiusbiologics.com/news-events/press-releases/detail/394/heat-biologics-inc-to-present-at-the-bio-ceo-investor-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/384/heat-biologics-inc-outlines-2015-corporate-objectives https://ir.scorpiusbiologics.com/news-events/press-releases/detail/374/heat-biologics-inc-presents-positive-immunological-data-on-hs-410-in-non-muscle-invasive-bladder-cancer-at-the-7th-annual-phacilitate-immunotherapy-forum-2015 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/364/heat-biologics-inc-to-present-at-the-7th-annual-phacilitate-immunotherapy-forum-2015 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/354/heat-biologics-inc-to-present-at-the-noble-financial-capital-markets-equity-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/344/heat-biologics-inc-expands-product-development-team-to-support-development-of-lead-product-candidates-in-oncology https://ir.scorpiusbiologics.com/news-events/press-releases/detail/334/heat-biologics-inc-to-present-at-the-piper-jaffray-26th-annual-healthcare-conference-on-december-2-in-new-york https://ir.scorpiusbiologics.com/news-events/press-releases/detail/324/heat-biologics-inc-reports-2014-third-quarter-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/314/heat-biologics-inc-commences-patient-dosing-of-phase-2-clinical-study-of-vesigenurtacel-l-for-the-treatment-of-bladder-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/304/heat-biologics-inc-completes-enrollment-of-phase-1-clinical-trial-of-vesigenurtacel-l-for-the-treatment-of-bladder-cancer-required-to-advance-to-phase-2 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/294/heat-biologics-inc-to-present-at-the-13th-annual-bio-investor-forum-in-san-francisco-on-tuesday-october-7-2014 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/284/heat-biologics-commences-patient-dosing-in-phase-2-study-of-viagenpumatucel-l-for-the-treatment-of-non-small-cell-lung-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/274/heat-biologics-inc-to-present-and-webcast-at-two-investor-conferences-in-september https://ir.scorpiusbiologics.com/news-events/press-releases/detail/264/heat-biologics-inc-closes-on-up-to-7-5-million-secured-term-loan-facility https://ir.scorpiusbiologics.com/news-events/press-releases/detail/254/heat-biologics-inc-reports-2014-second-quarter-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/244/heat-biologics-amends-bladder-cancer-protocol-for-early-advancement-into-phase-2-clinical-studies https://ir.scorpiusbiologics.com/news-events/press-releases/detail/234/heat-biologics-receives-green-light-to-expand-enrollment-of-its-phase-12-study-of-hs-410-in-bladder-cancer-based-on-encouraging-preliminary-safety-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/204/heat-biologics-inc-reports-2014-first-quarter-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/194/heat-biologics-inc-presents-proprietary-allogeneic-cell-line-antigen-screening-algorithm-and-systematic-analysis-of-combination-tumor-immunotherapy-preclinical-data-at-the-105th-annual-meeting-of-the-american-association-for-cancer-research https://ir.scorpiusbiologics.com/news-events/press-releases/detail/184/heat-biologics-inc-reports-2013-fourth-quarter-and-full-year-financial-results https://ir.scorpiusbiologics.com/news-events/press-releases/detail/177/heat-biologics-inc-to-present-at-the-maidstone-life-sciences-fourth-annual-cancer-immunotherapy-a-long-awaited-reality-conference-on-thursday-march-27-2014 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/176/heat-biologics-inc-submits-revised-protocol-to-fda-for-phase-2-clinical-study-of-hs-110-for-the-treatment-of-non-small-cell-lung-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/609/heat-biologics-inc-presents-preclinical-data-from-comparative-combination-cancer-immunotherapy-research-study-at-keystone-symposia-on-immune-evolution-in-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/175/heat-biologics-inc-appoints-taylor-h-schreiber-m-d-ph-d-as-vice-president-of-research-and-development https://ir.scorpiusbiologics.com/news-events/press-releases/detail/174/heat-biologics-commences-dosing-of-first-patient-in-phase-12-study-of-novel-cancer-immunotherapy-product-candidate-hs-410-for-the-treatment-of-bladder-cancer https://ir.scorpiusbiologics.com/news-events/press-releases/detail/14/heat-biologics-inc-to-present-at-16th-annual-bio-ceo-investor-conference-on-tuesday-february-11-2014 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/4/heat-biologics-inc-announces-formation-of-clinical-advisory-board-with-preeminent-immunotherapy-and-oncology-experts https://ir.scorpiusbiologics.com/news-events/press-releases/detail/164/heat-biologics-inc-to-present-at-ten-noble-financial-capital-markets-tenth-annual-equity-conference-on-tuesday-january-21-2014 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/154/heat-biologics-inc-to-present-at-biotech-showcase-2014 https://ir.scorpiusbiologics.com/news-events/press-releases/detail/134/heat-biologics-announces-its-phase-12-study-of-hs-410-in-bladder-cancer-is-open-for-enrollment https://ir.scorpiusbiologics.com/news-events/press-releases/detail/124/heat-biologics-inc-appoints-dr-anil-k-goyal-as-vice-president-of-business-development https://ir.scorpiusbiologics.com/news-events/press-releases/detail/144/heat-biologics-inc-to-present-at-25th-annual-piper-jaffray-healthcare-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/104/heat-biologics-successfully-completes-manufacturing-of-hs-410-to-start-phase-12-bladder-cancer-trial https://ir.scorpiusbiologics.com/news-events/press-releases/detail/114/heat-biologics-inc-reports-third-quarter-2013-financial-results-and-provides-clinical-programs-review https://ir.scorpiusbiologics.com/news-events/press-releases/detail/94/heat-biologics-inc-to-present-at-12th-annual-bio-investor-forum https://ir.scorpiusbiologics.com/news-events/press-releases/detail/84/heat-biologics-files-ind-for-bladder-cancer-product-candidate https://ir.scorpiusbiologics.com/news-events/press-releases/detail/74/heat-biologics-appoints-louis-c-bock-to-board-of-directors https://ir.scorpiusbiologics.com/news-events/press-releases/detail/54/heat-biologics-inc-to-present-at-aegis-capital-corp-2013-healthcare-conference https://ir.scorpiusbiologics.com/news-events/press-releases/detail/64/heat-biologics-inc-announces-partial-exercise-of-underwriters-over-allotment-option https://ir.scorpiusbiologics.com/news-events/press-releases/detail/44/heat-biologics-inc-announces-partial-exercise-of-underwriters-over-allotment-option https://ir.scorpiusbiologics.com/news-events/press-releases/detail/34/heat-biologics-inc-announces-closing-of-initial-public-offering-of-2500000-shares-of-common-stock https://ir.scorpiusbiologics.comhttps://www.scorpiusbiologics.com/privacy-policy https://ir.scorpiusbiologics.com/disclaimer https://ir.scorpiusbiologics.com/sitemap https://ir.scorpiusbiologics.com/accessibility-statement